|
|
| Line 1: |
Line 1: |
| {{drugbox
| |
| | IUPAC_name = 2-bromo-2-chloro-1,1,1-trifluoro-ethane
| |
| | image = Halothane2.png
| |
| | width=150px
| |
| | image2 = Halothane-3D-vdW.png
| |
| | width=150px
| |
| | CAS_number = 151-67-7
| |
| | ATC_prefix = N01
| |
| | ATC_suffix = AB01
| |
| | ATC_supplemental =
| |
| | PubChem = 3562
| |
| | DrugBank = APRD00598
| |
| | C=2 | H=1 | Br=1 | Cl=1 | F=3
| |
| | molecular_weight = 197.381 g/mol
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism = [[Liver|Hepatic]] ([[CYP2E1]]<ref>http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00598.txt</ref>)
| |
| | elimination_half-life =
| |
| | excretion = [[Kidney|Renal]]
| |
| | pregnancy_category =
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
|
| |
|
| {{SI}}
| |
|
| |
|
| |
|
| |
| ==Overview==
| |
| '''Halothane''' vapour (or '''Fluothane''') is an inhalational [[general anaesthetic]]. Its [[systematic name]] is 2-Bromo-2-chloro-1,1,1-trifluoroethane. It is the only inhalational [[anaesthetic agent]] containing a [[bromine]] atom. It is colourless and pleasant-smelling, but unstable in light. It is packaged in dark-coloured bottles and contains 0.01% [[thymol]] as a stabilising agent.
| |
|
| |
| ==Adverse effects==
| |
| All volatile anaesthetics such as halothane can trigger [[malignant hyperthermia]] in genetically susceptible individuals. The caffeine-halothane contracture test was developed to directly test muscle biopsy specimens for this susceptibility. This test may be replaced by genetic testing in the future.
| |
|
| |
| ==Related substances==
| |
| Chemically, halothane is not an [[ether]]. Attempts to find anaesthetics with less metabolism led to [[halogenated ethers]] such [[enflurane]] and [[isoflurane]]. The incidence of hepatic reactions with these agents is less. The degree of [[hepatotoxic]] potential of enflurane is controversial, although it is minimally metabolised. Isoflurane is essentially not metabolised and reports of associated liver injury are quite rare.
| |
|
| |
| ==Physical properties==
| |
| {|
| |
| |[[Boiling point]]: ||align=right| 50.2 °C || (at 101.325 kPa)
| |
| |-
| |
| |[[Density]]: ||align=right| 1.868 g/cm³|| (at 20 °C)
| |
| |-
| |
| |[[Molecular Weight]]: ||align=right| 197.4 [[unified atomic mass unit|u]]||
| |
| |-
| |
| |[[Vapor pressure]]: ||align=right| 244 mmHg || (at 20 °C)
| |
| |-
| |
| | ||align=right|288 mmHg || (at 24 °C)
| |
| |-
| |
| |[[Minimum alveolar concentration|MAC]]: ||align=right| 0.75 || vol %
| |
| |-
| |
| |Blood:Gas Partition coefficient: ||align=right|2.5
| |
| |-
| |
| |Oil:Gas Partition coefficient: ||align=right|224
| |
| |}
| |
|
| |
| ==History==
| |
| This halogenated [[hydrocarbon]] was first synthesised by [[Charles Suckling|C. W. Suckling]] of [[Imperial Chemical Industries]] (ICI) in 1951 and was first used clinically by M. Johnstone in Manchester in 1956. Halothane became popular as a nonflammable general anaesthetic replacing other [[volatile anaesthetics]] such as [[diethyl ether]] and [[cyclopropane]]. Use of the anesthetic was phased out during the 1980s and 1990s as newer anesthetic agents became popular. Halothane retains some use in [[veterinary medicine|veterinary]] [[surgery]] and in the Third World because of its lower cost.
| |
|
| |
| Halothane was given to many millions of adult and pediatric patients worldwide from its introduction in 1956 through the 1980s. Its properties include cardiac depression at high levels, cardiac sensitisation to [[catecholamines]] such as [[norepinephrine]], and potent bronchial relaxation. Its lack of airway irritation made it a common inhalation induction agent in pediatric anaesthesia. Due to its cardiac depressive effect, it was [[Contraindication|contraindicated]] in patients with cardiac failure. Halothane was also contraindicated in patients susceptible to cardiac arrythmias, or in situations related to high catecholamine levels such as pheochromocytoma.
| |
|
| |
| Repeated exposure to halothane in adults was noted in rare cases to result in severe [[liver]] injury. This occurred in about 1 in 35,000 exposures. The resulting syndrome was referred to as halothane [[hepatitis]], and is thought to result from the metabolism of halothane to [[trifluoroacetic acid]] via oxidative reactions in the liver. About 20% of inhaled halothane is metabolised by the liver and these products are excreted in the urine. The hepatitis syndrome had a mortality rate of 30% to 70%. Concern for hepatitis resulted in a dramatic reduction in the use of halothane for adults. It was replaced in the 1980s by enflurane and isoflurane. By the year 2005 the common volatile anaesthetics in use were [[isoflurane]], [[sevoflurane]], and [[desflurane]]. Since the risk of halothane hepatitis in children was substantially lower than in adults, halothane saw continued use in pediatrics in the 1990s. However, by the year 2000 [[sevoflurane]] had largely replaced the use of halothane in children.
| |
| ==References==
| |
| *Atkinson, Rushman, Lee. ''A Synopsis of Anaesthesia''. 1987.
| |
| *Eger, Eisenkraft, Weiskopf. ''The Pharmacology of Inhaled Anesthetics''. 2003.
| |
| <references/>
| |
|
| |
| ==External links==
| |
|
| |
| {{General anesthetics}}
| |
|
| |
| [[de:Halothan]]
| |
| [[es:Halotano]]
| |
| [[fr:Halothane]]
| |
| [[it:Alotano]]
| |
| [[nl:Halothaan]]
| |
| [[ja:ハロタン]]
| |
| [[pt:Halotano]]
| |
| [[ru:Фторотан]]
| |
|
| |
| [[Category:Anesthetics]]
| |
| [[Category:Hepatitis]]
| |
| [[Category:Organohalides]]
| |
| [[Category:Drugs]]
| |
|
| |
| [[pl:Halotan]]
| |
|
| |
| {{jb1}}
| |
| {{WH}}
| |
| {{WikiDoc Sources}}
| |